Clinical Trial Update: Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients [Phase 1]

View source ↗

Summary

A Phase 1 pharmacodynamics study comparing a single subcutaneous dose of SAR113244 to placebo in patients with systemic lupus erythematosus was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAR113244

Snippet

Sponsor: Sanofi | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: WITHDRAWN